Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-12-06
2010-10-19
Belyavskyi, Michail A (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S372000
Reexamination Certificate
active
07816088
ABSTRACT:
Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the bcatenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.
REFERENCES:
patent: 6465247 (2002-10-01), Weissman et al.
patent: 6761883 (2004-07-01), Weissman et al.
patent: 6908763 (2005-06-01), Akashi et al.
patent: 7217568 (2007-05-01), Jamieson et al.
patent: 2003/0119080 (2003-06-01), Mangano
patent: 2004/0171559 (2004-09-01), Weissman et al.
patent: 2007/0238127 (2007-10-01), Jamieson et al.
patent: WO9910478 (1999-03-01), None
patent: WO 01/92877 (2001-12-01), None
Dührsen, U., et al., “Self-renewal and differentiation of stem cells in a bipotential murine leukemia: an in vitro model for differentiation therapy,” (1994)Blood, 83(9):2627-2636.
Jamieson, C., et al,, “Expression by highly purified chronic myelogenous leukemic hematopoietic stem cells and myeloid progenitors pre and post-imatinib therapy,” (2003)Blood, 102(11:Abstract #1519.
Kussick, S., et al., “Acute myeloid leukemia bearing the Flt3 internal tandem duplication has a unique immunophenotype which enables its identification by flow cytometry,” (2002)Blood, 100(11):Abstract #737.
Petzer, A., et al., “Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chornic myeloid leukemia,” (1996)Blood, 88(6):2162-2171.
Testa, U., et al., “Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors,” (2002)Blood, 99(12):4634-4637.
Akashi et al., “A clonogenic common myeloid progenitor that gives rise to all myeloid lineages”, Nature, 2000, 404 (6774):193-7.
Kondo et al., “Identification of clonogenic common lymphoid progenitors in mouse bone marrow”, Cell, 1997, 91 (5):661-72.
Kondo et al., “Biology of hematopoietic stem cells and progenitors: implications for clinical application” Annu. Rev. Immunol, , 2003, 21:759-806.
Onida et al., “Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients”Blood, , 2002, 99(3):840-849.
Ailles Laurie
Jamieson Catriona Helen M.
Weissman Irving L.
Belyavskyi Michail A
Bozicevic Field & Francis LLP
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Identification, isolation and elimination of cancer stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification, isolation and elimination of cancer stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification, isolation and elimination of cancer stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171368